Twist Bioscience has filed a patent for methods and compositions related to libraries of optimized antibodies. The patent describes nucleic acids encoding modified sequences for antibodies targeting Dickkopf WNT signaling pathway inhibitor 1 (DKK1). The patent also mentions protein libraries generated from these nucleic acids and cell libraries expressing the nucleic acid libraries. GlobalData’s report on Twist Bioscience gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Twist Bioscience, Water gas shift catalysts was a key innovation area identified from patents. Twist Bioscience's grant share as of September 2023 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Optimized antibody libraries encoding dkk1 antibodies
A recently filed patent (Publication Number: US20230312749A1) describes an antibody or antibody fragment that can potentially be used for therapeutic purposes. The patent claims specify the characteristics and properties of the antibody or antibody fragment.
According to the claims, the antibody or antibody fragment must have a variable domain, heavy chain region (VH) with an amino acid sequence that is at least 90% identical to the sequences provided in the patent. These sequences are listed as SEQ ID NOs: 295-392, 394-712, or 2164-2258. The antibody or antibody fragment should also bind to a spike glycoprotein and specifically to the receptor binding domain of the spike glycoprotein.
The patent further states that the antibody or antibody fragment should have a KD (dissociation constant) of less than 50 nM, indicating a strong binding affinity. Additionally, the patent provides options for even stronger binding affinities, with KD values of less than 25 nM, 10 nM, or 5 nM.
The antibody or antibody fragment can be of various types, including monoclonal antibodies, polyclonal antibodies, bi-specific antibodies, multispecific antibodies, grafted antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, camelized antibodies, single-chain Fvs (scFv), single chain antibodies, Fab fragments, F(ab')2 fragments, Fd fragments, Fv fragments, single-domain antibodies, isolated complementarity determining regions (CDR), diabodies, fragments comprised of only a single monomeric variable domain, disulfide-linked Fvs (sdFv), intrabodies, anti-idiotypic (anti-Id) antibodies, or antigen-binding fragments thereof. The patent also mentions the possibility of the antibody being a single domain antibody.
In addition to the VH region, the patent also describes a nucleic acid composition that includes a first nucleic acid encoding a variable domain, heavy chain region (VH) with specific complementarity determining regions (CDRH1, CDRH2, and CDRH3). The amino acid sequences of these CDR regions are provided in the patent. The nucleic acid composition may also include an excipient.
Similarly, the patent describes an antibody or antibody fragment with a variable domain, light chain region (VL) that is at least 90% identical to the sequences provided in the patent (SEQ ID NOs: 713-918). This antibody or antibody fragment should also bind to a spike glycoprotein and specifically to the receptor binding domain of the spike glycoprotein. The KD values and the types of antibodies or antibody fragments mentioned for the VH region also apply to the VL region.
Overall, this patent provides detailed claims for antibodies or antibody fragments with specific characteristics and binding properties. These antibodies or antibody fragments have the potential to be used in therapeutic applications, particularly in targeting spike glycoproteins.
To know more about GlobalData’s detailed insights on Twist Bioscience, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
